Kinetic Analysis of BCL11B Multisite Phosphorylation—Dephosphorylation and Coupled Sumoylation in Primary Thymocytes by Multiple Reaction Monitoring Mass Spectroscopy

Walter K. Vogel,† Philip R. Gafken,§ Mark Leid,‡§ and Theresa M. Filtz*†

1Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon 97331, United States
2Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, United States
3Integrative Biosciences Department, School of Dentistry, Oregon Health & Science University, 611 Southwest Campus Drive, Portland, Oregon 97239-3097, United States

Supporting Information

ABSTRACT: Transcription factors with multiple post-translational modifications (PTMs) are not uncommon, but comprehensive information on site-specific dynamics and interdependence is comparatively rare. Assessing dynamic changes in the extent of PTMs has the potential to link multiple sites both to each other and to biological effects observable on the same time scale. The transcription factor and tumor suppressor BCL11B is critical to three checkpoints in T-cell development and is a target of a T-cell receptor-mediated MAP kinase signaling. Multiple reaction monitoring (MRM) mass spectroscopy was used to assess changes in relative phosphorylation on 18 of 23 serine and threonine residues and sumoylation on one of two lysine resides in BCL11B. We have resolved the composite phosphorylation—dephosphorylation and sumoylation changes of BCL11B in response to MAP kinase activation into a complex pattern of site-specific PTM changes in primary mouse thymocytes. The site-specific resolution afforded by MRM analyses revealed four kinetic patterns of phosphorylation and one of sumoylation, including both rapid simultaneous site-specific increases and decreases at putative MAP kinase proline-directed phosphorylation sites, following stimulation. These data additionally revealed a novel spatiotemporal bisphosphorylation motif consisting of two kinetically divergent proline-directed phosphorylation sites spaced five residues apart.

KEYWORDS: BCL11B, MRM, post-translational modification, signal transduction, SRM, sumoylation, T-cell receptor

INTRODUCTION

PTMs are the key regulatory handles responsible for altering the functional state of cellular proteins. Individually, in multiples, or in combinations, they can alter secondary structure, enzymatic activity, protein–protein and protein–complex interactions, subcellular localization, and thermodynamic or regulated stability. These finely coordinated modifications are critical to proper cell function; miscoordination of these PTMs, including PTMs of transcription factors, is associated with aberrant cell function and disease. Site-specific DNA-binding transcription factors directly regulate gene expression to control everything from the very nature of a cell—coordinating development through functional maturity—to finely tuned and subtype responses to internal and external cues. Having no constitutive enzymatic activities, transcription factors are the orchestrating nucleus for associating enzymatic complexes and are themselves the target and integrator of cellular signals in the form of PTMs. The site-specific transcription factor BCL11B is required for postnatal life and proper development of skin, teeth, and the nervous system. BCL11B is essential to the development and function of the adaptive immune response and is highly expressed in the T-cell lineage. Circulating T-cell subtypes develop in the thymus, where BCL11B serves as a master regulator and determining transcription factor for T-cell lineage commitment. The latter stages of thymocyte development are regulated by activation of the TCR and downstream MAP kinase pathways, which in turn activate a gene network sufficient for the T-cell maturation program (positive selection) or for induction of apoptosis (negative selection). Knockout of BCL11B blocks T-cell development. In late-maturing DP thymocytes, BCL11B regulates expression of approximately 900 genes and functions as a repressor in the context of the NuRD complex of proteins at a majority of the sites but functions as an activator at a minority (33%). In humans, haploinsufficiency of BCL11B is linked to T-cell acute lymphoblastic leukemia and adult T-cell leukemia/lymphoma; BCL11B overexpression is associated with acute myeloid leukemia and head and neck squamous cell carcinoma. In mice,
haploinsufficiency of BCL11B increases susceptibility to radiation-induced lymphomas and lymphoblast crisis.\textsuperscript{22}

BCL11B is a highly phosphorylated transcription factor with more than 50 sites in human and 37 in mouse tissues reported to date.\textsuperscript{23} In mouse primary thymocytes, we previously identified 23 serine/threonine phosphorylation sites and two sites of sumoylation of BCL11B.\textsuperscript{24} Our study showed that BCL11B is modified by phosphorylation and sumoylation in resting thymocytes (90\% of which are DP cells) and responds dynamically to activation of the MAP kinase signaling pathway. Activation leads to the following composite changes in BCL11B: (1) a rapid increase in phosphorylation and coincident loss of basal sumoylation that is followed by (2) simultaneous dephosphorylation and resumoylation and (3) subsequent ubiquitination and proteasomal degradation. BCL11B phosphorylation is mediated by both ERK1/2 and p38 MAP kinases, but the slower dephosphorylation is dependent on ERK1/2-activated protein phosphatases. The sumoylation state of BCL11B is dependent on the activity of associated SENP desumoylating enzymes, and this activity is promoted by BCL11B phosphorylation. The consequence of these sequential PTM changes is the apparent conversion of BCL11B from a repressor to an activator of transcription at the model target gene, \textit{Id2}.

The role(s) of BCL11B PTMs is underexplored in normal thymocyte function as are the consequences of its dysregulation in oncogenesis. Tandem mass spectrometry was used to directly identify the principal sumoylation site (for both SUMO1 and SUMO2/3).\textsuperscript{24} However, despite the identification of a linkage between phosphorylation and desumoylation, we lacked phosphorylation site-specific kinetic information needed to efficiently interrogate functional effects of BCL11B PTMs efficiently. To define the functionally relevant phosphosite alterations that precede or complement sumoylation to regulate BCL11B activity, resolution of the kinetics of phosphorylation/ dephosphorylation of individual phosphosites—including those occurring on multiply-phosphorylated peptides—is required over a time course of activation that corresponds to changes in transcriptional activity.

The current report is focused on resolving the dynamics of phosphorylation and sumoylation on BCL11B in a native cell system, that is, thymocytes, with naturally limited protein levels using multiple reaction monitoring-mass spectrometry (MRM-MS). Detailed kinetic characterization has the potential to distinguish the most relevant PTMs of highly modified proteins and narrow the combinatorial scope of lower throughput methods that seek to define the function of identified PTMs. We characterized the relative PTM dynamics of the majority of BCL11B phosphosites and its principal sumoylation site and grouped these sites into kinetically concerted subpopulations.

\section*{MATERIALS AND METHODS}

\subsection*{Primary Cell Culture and Treatment}

Primary mouse thymocytes were isolated from 5–7 week old mice and cultured at 37 °C in RPMI 1640 media supplemented with 2.5\% fetal bovine serum (HyClone) for 6 h prior to chemical stimulation. All procedures involving mice were conducted with approval of the Oregon State University Institutional Animal Care and Use Committee. Thymocytes were stimulated with 100 nM phorbol 12,13-dibutyrate (LC Laboratories, Woburn, MA) and 500 nM A23187 (Calbiochem), or with DMSO (vehicle control), for between 7 and 60 min to activate cell signaling pathways in a manner similar to native T-cell activation.\textsuperscript{25,26}

\subsection*{Protein Extraction and Sample Preparation}

Immediately after treatment, cultured thymocytes were diluted in ice-cold PBS, centrifuged, and lysed in 10 volumes of rapid detergent lysis buffer (20 mM HEPES, pH 7.4; 200 mM NaCl; 50 mM NaF; 2 mM EDTA; 10\% glycerol; 0.1 mM PMSF; 1 μg/mL peptatin A; 5 μg/mL leupeptin; 10 μM E64; 10 μM N-ethylmaleimide; and 1\% SDS) and placed in a boiling water bath for 15 min. Denatured protein extracts were sonicated to shear DNA and diluted 10-fold in the same buffer lacking SDS but containing 1.1% Triton-X100. Two monoclonal anti-BCL11B antibodies (clones 2S5B6, Abcam ab18465 and 6A10, mAbDx, Cambridge, MA) were used together, each at 0.25 μg/mL, to immunoprecipitate denatured BCL11B from dilute extracts. BCL11B samples were gel purified from protein G agarose immune complexes by SDS-PAGE, and peptides were prepared for analysis by sequential cyanogen bromide cleavage and trypsin digestion. In-gel cyanogen bromide digests (200 mM cyanogen bromide in 70\% trifluoroacetic acid) were conducted at room temperature for 12–14 h, protected from light in a fume hood. Warning: cyanogen bromide is toxic, volatile, and decomposes to HCN gas. Volatile reactants were removed from the gel slices by centrifugal vacuum concentration, neutralized with ammonium bicarbonate, and dehydrated in acetonitrile. Prior to tryptic digestion, the dried gel slices were rehydrated and reduced in 25 mM dithiothreitol/50 mM ammonium bicarbonate for 30 min at 50 °C, alkylated in 50 mM 2-chloroacetamide/50 mM ammonium bicarbonate for 30 min at room temperature, and dehydrated again in acetonitrile. In-gel tryptic digests were conducted in 0.025% ProteaseMax (Promega, Madison, WI) and 50 mM ammonium bicarbonate for 3 h at 37 °C. Product peptides were extracted from gel slices in 0.01% ProteaseMax and 50 mM ammonium bicarbonate, acidified with trifluoroacetic acid, and concentrated by vacuum centrifugation. This double-cleavage procedure permitted the efficient analysis of phosphorylation on Ser169, Ser177, Ser401, and Thr416, and sumoylation on Lys679. The signals from the resulting shorter peptides were more easily observed, and the site-specific resolution of phospho-Ser401 from phospho-Thr416 was facilitated by analyzing these modifications on separate peptides generated from the cleavage at Met412. Cyanogen bromide cleavage also facilitated the analysis of sumoylation by reducing the size of the SUMO moieties from between 19 residues (SUMO1) and 34 residues (SUMO2 and SUMO3) to 15 residues. The cleavage products of SUMO2 and SUMO3 are indistinguishable; consequently, we report the combined modification by both of these subtypes (see Figures 1 and 2, Supporting Information for outlines of sample preparation).

\subsection*{Targeted Mass Spectrometry Analysis}

Sample solutions were analyzed on a Thermo TSQ Vantage triple-quadrupole mass spectrometer (Thermo-Fisher Scientific, Waltham, MA) in the MRM mode. The mass spectrometer used the Xcalibur control software (version 2.1) with Thermo EZ-Tune (version 2.3 SP1) and was coupled to an Eksigent NanoLC 2-dimensional HPLC system (Dublin, CA) with a Peltier cooled (model AS-1) autosampler. A 10 μL sample was loaded onto a 2 cm × 100 μm inner diameter IntegraFrit trap column (New Objective, Woburn, MA) packed with Magic C\textsubscript{18} 200 Å pore size, 5 μm diameter reverse-phase resin (Michrom Bioresources, Auburn, CA) and eluted from a 21 cm × 75 μm
inner diameter PicoFrit capillary column (New Objective) packed with Magic C₁₈ reverse-phase resin (100 Å, 5 μm) using a 45 min gradient from 2−40% solvent B in solvent A, followed by a 5 min gradient to 60% solvent B and then a 1 min gradient to 95% solvent B at a flow rate of 400 nL/min, where solvent A was 0.1% formic acid in water, and solvent B was 0.1% formic acid in acetonitrile. The solvents used were LC−MS grade from Burdick & Jackson (Morristown, NJ). Spectra were acquired over a 75 min period using a resolution of 0.7 (fwhm) in both Q₁ and Q₃, a chrom filter peak width of 10 s, and a collision gas pressure on Q₂ of 1.2 mTorr. The spray voltage used was set at a value to establish a stable spray, which ranged between 1850−2100 V, and the capillary temperature was set to 275 °C.

**Quantitative Multiple Reaction Monitoring Analysis**

Analytical precursor/product ion pair transitions were chosen from a spectral library generated using BiblioSpec (version 2)²⁷ from Thermo LTQ-FT tandem mass data³⁴ and optimized on a TSQ Vantage triple-quadruple mass spectrometer with respect to collision energy.²⁸ Skyline (version 1.3)³⁹ MRM analysis software was used to generate a series of collisional energy (CE) optimization methods for the mass spectrometer. Unscheduled transition lists were exported into 15 MRM-mode instrument methods to allow higher scan time (15 ms) analysis of transitions. For each transition, a range of collisional energy voltages spanning ±5 V from a theoretically calculated optimal value were recorded, and these qualification runs were evaluated in Skyline. The CE voltage that yielded the highest intensity peak for each peptide was determined to be the optimal value (see Figure 3, Supporting Information for transitions to spectra library matches used in this study). The scan time used in the finalized transition list was 8 ms.

Relative quantitative analysis was based on the sum of precursor/product ion pair total ion currents of PTM-containing peptides normalized to total BCL11B represented by unmodified BCL11B peptides. Analytical transitions were recorded for each peptide, and site-specific transitions were chosen to resolve phosphorylations on multiply-phosphorylated peptides. See Figure 1 for an outline of analytical procedures and Table 1 of the Supporting Information for a listing of transitions used in these analyses. Our choices for normalization peptides in this highly modified protein were limited as many of the best candidates contained known or potential phosphorylation sites. We used a pair of BCL11B tryptic peptides lacking known or potential phosphorylation sites, ⁴³⁷FQSNLVHR⁴⁴⁵ and ⁶¹⁴GGAPGAEPPALFPR⁶⁵⁷, for signal normalization in most instances (the signals used to quantify these peptides are shown in Figure 4, Supporting Information). An alternative normalization procedure used the nonphosphorylated version of analyzed peptides, where possible, for the peptide products of cyanogen bromide cleavage as the efficiency of this reaction was variable. Cyanogen bromide will not cleave oxidized methionine residues,³⁰ and the source of this variability was likely sample differences in the degree of methionine oxidation. Use of these nonphosphorylated peptides for normalization was an effective internal sample control. Phosphorylations at Thr376 and Ser381 were quantified as the unweighted mean of the normalized signals from two peptides; all other sites were quantified from a single peptide. Data from two independent biological replicate samples are reported.
chromatograms and the spectral library are available for viewing at https://panoramaweb.org/labkey/project/OSU%20Filtz%20Group-supplementary_data/Vogel-2014-begin.view? and are available from the same location for download as Skyline files (Skyline software is freely available at https://skyline.gs.washington.edu).

RESULTS AND DISCUSSION

The kinetics of phosphorylation of individual sites in multiply-phosphorylated proteins is greatly understudied and yet is critical to accurately determine the mechanistic role of post-translational modifications in regulation of protein function. Most PTMs are viewed as binary switches in which presence or absence controls a discrete protein function or location. In multiply-modified proteins, the potential tertiary structures or modification states increase as do the opportunities for fine-tuning response or for variation in function. Currently, mass spectrometric techniques used to identify PTMs are far more efficient than methods available to assess the functional relevance of the modifications. Two strategies are generally used to identify functional effects of PTMs. The first strategy is to develop site-specific antibodies selective for modified states of the protein and probe under various conditions to correlate modification with function. This method is robust and applicable to native tissues; however, developing and validating antibodies requires a significant investment of time and resources and is impractical as a survey method. The second strategy is mutagenesis of the modified site to a nonmodifiable amino acid or mutagenesis to a mimic (e.g., mutation to glutamate to mimic a phosphosite) followed by assessment of function. However, the study of highly modified proteins by mutagenesis of individual sites presents significant difficulty in that combinatorial possibilities can overwhelm experimental designs. Although a few reports exist in which clusters of relevant PTMs were identified by simultaneous multisite mutants (e.g., the roles of combinations of 26 phosphosites in the plant transcription factor PIF323), we have had only limited success in the identification of the function of specific phosphorylation sites after numerous single and multiphosphosite mutants of BCL11B were created. To more efficiently identify functional clusters of PTMs on BCL11B, we hypothesized that functional states of the protein are likely to temporally correlate to the PTM kinetics of individual sites. To most accurately link PTMs to temporally distinct functions, we sought to quantify the kinetics of modification of individual amino acid residues over the functional time course in the native system, DP thymocytes.

Given these constraints, we selected MRM-MS to attempt comprehensive quantification of relative modifications of all identified sites of BCL11B over a time course of activation. A recent study by Zheng and colleagues33 used MRM-MS analysis to link five phosphosites in the scaffolding protein SHC1 to at least three distinct phosphorylation states that temporally correlated with segregated functional outcomes following EGF receptor stimulation. The challenge that we faced was to perform a similar MRM-MS analysis but in a native tissue source with its normal repertoire of PTM modifying enzymes at naturally limited protein levels and to simultaneously quantify 23 previously identified phosphorylation sites.

BCL11B PTMs were assessed by MRM-MS basally and at three time points based on previous estimates of the maxima of each PTM following the initiation of MAP kinase stimulation by PDBu/A23187 to quantify site-specific dynamics in primary mouse thymocytes. The stimulation time points also encompass the time frame in which BCL11B functionally shifts from association with a repressed to an activated Id2 target gene. Sample PTMs were preserved by rapid whole-cell denaturation; the target protein was enriched by immunoprecipitation and gel purified prior to analysis. Analytical transitions were chosen to quantify PTM-containing peptides, and site-specific transitions were chosen for multiply-phosphorylated peptides. The method effectively resolved the site-specific phosphokinetics of multiply-phosphorylated peptides and allowed us to quantify 18 of 23 phosphorylation sites. Our results are consistent with a more limited previous report that BCL11B is dynamically phosphorylated at four specific sites in TCR-stimulated human leukemia T (Jurkat)-cells. For the analysis of BCL11B sumoylation, fragment ions encompassing the entire tryptic pentapeptide and between 2 and 11 residues of the SUMO moieties were chosen. Relative PTM quantification efficiently served the primary purpose of identifying amplitude and kinetics of dynamically modified residues. Absolute quantification can be accomplished by the use of stable isotope-labeled internal standard peptides, but given 23 sites to monitor, this would have been needlessly costly for our purposes.

MRM analysis is commonly used to quantify proteins from complex mixtures in proteomic studies by identifying a few experimentally well-behaved peptides and selectively monitoring a few of the most intense collisionally induced precursor/product ion pairs. However, the single-protein, multisite analyses performed herein did not allow the freedom to choose the most intense peptides. Therefore, the signals obtained and quantified in this study are generally smaller than those expected for a proteomic study. The low stoichiometric ratio typical of many PTMs imposes an additional analytical limitation. Despite the increase in sample size, data for five additional phosphorylation sites previously identified24 were not sufficiently robust to permit site-specific quantification.

Sumoylation Is More Easily Assessed with Cyanide Bromide Cleavage

BCL11B has two known sumoylation sites: the principal site, Lys679, was identified in situ by tandem mass spectrometry; and a secondary site, Lys877, which is not amenable to mass spectrometry analysis, was identified from the results of site-directed mutagenesis. Our analysis of BCL11B sumoylation was limited to the modification of the experimentally accessible Lys679 by SUMO1 and SUMO2/3 and was aided by the combined use of cyanogen bromide cleavage and trypsin digestion, which provided a significant advantage over trypsin alone for the analysis of sumoylation. Cyanogen bromide cleaves the SUMO side chains to 15 amino acid residues for all subtypes and reduces the number of isoforms that result from missed trypsin cleavage (relevant to the analysis of SUMO2/3). These shortened SUMO moieties retain the same sequence distinction as the trypsin-only digestion products and for most peptides are expected to be predominantly observed as 3+ charge state ions when analyzed by electrospray ion sources. The signals generated by these smaller branched-chain peptides proved sufficient for the current analysis. Cyanogen bromide/tryptic preparations may be generally useful for the mass spectrometric analysis of sumoylation.

The kinetics of Lys679-specific sumoylation quantified by MRM-MS are similar to the nonsite-specific quantitative immunoblot analysis (Figure 5, Supporting Information).
Sumoylation decreased rapidly upon thymocyte stimulation, followed by resumoylation to a level greater than basal by 60 min. Sumoylation often results in the multimeric attachment of SUMO moieties to a single lysine residue that forms polymeric chains, potentially of mixed subtypes, and was observed for BCL11B in this context (see Figure 5, Supporting Information and ref 24). Immunological methods are sensitive to the total number of SUMO moieties, but the mass spectrometric methods employed in the current report are sensitive only to the covalent attachment stoichiometry at the target lysine residue.

BCL11B may be ideally suited to the study of sumoylation dynamics in a native, functionally relevant cell population. Its principal sumoylation site is located on a small tryptic peptide five amino acids in length, which places this modification within the analytical range of current targeted mass spectrometric techniques. In contrast, a typical sumoylated peptide analyte is expected to be the length of two typical tryptic peptides modified by the addition of a 15 amino acid SUMO moiety. In addition, BCL11B is natively expressed at high levels in thymocytes, a cell population that is highly homogeneous and easily isolated from the thymus. Finally, the dynamics of BCL11B PTMs are easily and relevantly affected as demonstrated in the current report.

**Kinetic Classification of BCL11B Post-Translational Modifications**

Kinetic characterization of the phosphorylation sites revealed that the composite phosphorylation status of BCL11B previously observed over the stimulation time course was not the result of simultaneous, kinetically concerted alterations of all sites. Rather, resolution of the sumoylation and phosphorylation kinetics of individual sites allowed us to classify distinct PTM states of BCL11B. Phosphosites were categorized into four groups based on relative changes in the stoichiometry of phosphorylation. Phosphorylation of four sites increased rapidly and reached a maximum at 7 min post-stimulation, which decreased from there (shown in red in Figure 2). A second group of six sites (shown in green in Figure 2) lost phosphorylation relative to basal and reached a minimum at either 7 or 30 min. For a third group of four sites (shown in blue in Figure 2) phosphorylation remains elevated. Sites insensitive to stimulation were shown in black; and sumoylations at Lys679 are shown in orange. Data points are the mean of two biological replicates, and the vertical bars represent the range of these data values. Data points without vertical bars did not vary beyond the width of the plotting point between the two data sets.
blue), stimulation resulted in a general increase in phospho-stoichiometry that was relatively insensitive to phosphatase activity when compared to the red sites. The fourth group of three sites appeared to be relatively insensitive to stimulation (shown in black in Figure 2).

A summary model of these data reveals that MAP kinase stimulation elicits four successive states evident in the changing PTM pattern of BCL11B (Figure 3). The model is partially informed by estimates of the extent of phosphorylation derived from relative phosphorylation changes (Figure 2) and comparable differences between the phosphopeptides and nonphospho-modified versions of those peptides. The basal state of the protein is sumoylated on Lys679 and phosphorylated on selected residues (green bars in Figure 3). MAP kinase stimulation simultaneously results in rapid selective dephosphorylation of some basally phosphorylated residues and increased phosphorylation at other sites. Some of the increased phosphorylation sites are relatively sensitive to phosphatase(s) and rapidly dephosphorylate (red bars), while others are not (blue bars). Stimulation also results in an initial rapid decrease in sumoylation at Lys679. Thirty minutes after the onset of stimulation, phosphorylation has reached an overall minimum, and sumoylation levels have returned to near basal. By 60 min poststimulation, the phosphorylation status of BCL11B is dominated by the kinase sensitive/phosphatase insensitive sites (blue bars), and the sumoylation state is markedly in excess of basal. The most dynamically altered amino acids fall within range of the central BCL11B protein–protein interaction domain (PPID 1, Figure 3).38–41

**Desumoylation and Resumoylation Occur in Different Phospho-BCL11B Contexts**

The integration of extracellular signals and resulting changes in gene expression patterns are mediated by changes in PTM status of transcription factors and associated cofactors. DP thymocytes are a quiescent cell type; poised for both activation and apoptosis, they are the progenitor of numerous circulating T-cell subtypes and serve as a developmental checkpoint. BCL11B is essential as its regulated activation is critical to the adaptive immune response. In the basal state, the transcription factor BCL11B is the repressor of some genes and the activator of others. Upon cellular activation, BCL11B appears to switch from a basal repressor to a net activator of at least some of these genes via a process that involves both desumoylation and resumoylation linked to changes in phosphorylation. While there are multiple phosphorylation site changes, these assume three distinct states in thymocytes in response to stimulation. Basal sumoylation exists in one of these states; the rapid desumoylation occurs while BCL11B assumes a second phosphorylation state, and the subsequent resumoylation occurs while BCL11B is in a third state. Previous work had suggested no more than a simple inverse relationship between sumoylation and phosphorylation. The current report clearly indicates that resumoylation, returning to near basal levels by about 30 min and increasing to a maximum at about 60 min, occurs in the context of a phosphorylation state that is very different from that which exists under basal conditions (Figure 3). The results of this analysis suggest that a particular combination of phosphorylation sites in the presence of sumoylation is needed to specify the activity state of BCL11B-occupied promoters.

![Model of BCL11B post-translational modification states](image)

Figure 3. Model of BCL11B post-translational modification states. Kinetic data show that PTM status is a succession of discrete states. Bar heights indicate the relative degree of phosphorylation and sumoylation of BCL11B basally and at time points following PDBu/A23187 stimulation of primary mouse thymocytes. The bar colors are described in Figure 2, and phosphorylation sites lacking kinetic data are shown in white. The central protein–protein interaction domain for HP1α, SIRT1, CoupTF, SP1, and NuRD complex members RbAp46 and RbAp48 (PPID 1) and the carboxy-terminal protein–protein interaction domain for CoupTF, HP1α, and SP1 (PPID 2) are indicated by vertical gray bars. Phosphorylations of residues Ser95 and Ser96 are combined and represented as a single bar.
Identification of a Novel Spatiotemporal Bisphosphorylation Motif

The kinetic resolution obtained in these studies also allowed for identification of two instances of a previously unidentified spatiotemporal protein phosphorylation motif, pTPPXxpSP in BCL11B, the subsites of which share a similar kinetic and directional response to MAP kinase stimulation. Shown in Figure 2 and schematically in Figure 3, both threonines (Thr313 and Thr376) are relatively phosphorylated in the basal state, while the serines (Ser318 and Ser381) are relatively unphosphorylated. Upon MAP kinase stimulation, the threonines are rapidly dephosphorylated, while the serines phosphorylated, which suggests differential sensitivity of the sites to kinase and phosphatase. The effect of cellular stimulation is to switch the dominant phosphosite on both motifs from the threonine to the serine residues.

The closest analogous example of this motif occurs in the transcription factor MYC. This extensively studied protein is activated and degraded by sequential phosphorylation—dephosphorylation on a closely spaced pair of proline-directed phosphorylation sites. MYC is sequencially phosphorylated first at Ser62 and then at Thr58 by different kinases, the first of which activates and stabilizes the protein, while the second is required for the binding of PIN1, the consequent cis/trans-isomerization of Pro63, and the degradation promoting dephosphorylation of phospho-Ser62 by a trans-specific phosphatase. These motifs, while similar at the amino acid sequence level, differ in the sequential ordering of phosphorylation and dephosphorylation and in the consequence of dephosphorylation.3,42

This BCL11B motif is relatively uncommon in that it occurs singly in approximately 60 human proteins, half of which are known to be phosphorylated (see Table 3, Supporting Information) and three of which have known functional relevance, including in the cardiac hypertrophic response mediated by the transcription factor GATA4.2,3,44 BCL11B uniquely contains two examples of the motif that both occur in the middle of the central protein–protein interaction domain (Figure 3). While the microscopic mechanism underlying the switch in the motif is likely rooted in the differential sensitivity to signal-activated protein phosphatases, the macroscopic effect may be as a signal coincidence detector for the dual activation of both relevant kinases and phosphatases.

CONCLUSION

MAP kinase activation in thymocytes results in a complex pattern of multisite phosphorylation, dephosphorylation, desumoylation, and resumoylation on the target transcription factor BCL11B. While these results are consistent with the simultaneous action of ERK- and p38-mediated phosphorylation and ERK-stimulated phosphatase action,34 the resulting multiple kinetic patterns are unusual. Multisite phosphorylation/dephosphorylation is often observed to be concerted and sometimes positively cooperative, which results in switch-like mechanisms.35–40 The four kinetic patterns of phosphorylation we observe suggest a complicated PTM-mediated regulatory scheme that requires the action of multiple enzymes, the interplay of which remains to be defined. The bisphosphorylation motif described above may be an example of this complexity.

ASSOCIATED CONTENT

Supporting Information

Transitions used to quantify changes in BCL11B post-translational modifications; relative quantification of BCL11B post-translation modifications; human proteins with the TPxxP motif; outline of BCL11B sample preparation; BCL11B sample preparation: gel purification; spectra database matches for analyzed peptides; relative quantification of BCL11B peptides used to normalize PTM-containing peptide signals; and quantitative immunoblot analysis of BCL11B sumoylation. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author
*E-mail: Theresa.fitze@oregonstate.edu. Phone: 541-737-5802. Fax: 541-737-3999.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors wish to thank Brian Milless and Fred Hutchinson Cancer Research Center for invaluable technical support, Jeff Morré and the Environmental Health Sciences Center Mass Spectrometry Facility at Oregon State University (supported by NIEHS, National Institutes of Health Center Grant No. ES000210) for preliminary data, and Diana Eng and Chrissa Kioussis (Oregon State University) for help with mouse husbandry. Research reported in this publication was supported by the National Institute of General Medical Science of the National Institutes of Health under award number R15 GM096243 (to T.M.F.) and by funds provided by the Oregon State University College of Pharmacy.

ABBREVIATIONS

DP, double-positive thymocytes; MRM, multiple reaction monitoring; NuRD, nucleosome remodeling and deacetylation; PDBu, phorbol 12,13-dibutyrate; PTM, post-translational modification; SUMO, small ubiquitin-like modifier; TCR, T-cell receptor

REFERENCES

(1) Filtz, T. M.; Vogel, W. K.; Leid, M. Regulation of Transcription Factor Activity by Interconnected Post-Translational Modifications. Trends Pharmacol. Sci. 2014, 35, 76–85.

(2) van Berlo, J. H.; Elrod, J. W.; Aronow, B. J.; Pu, W. T.; Molkentin, J. D. Serine 105 Phosphorylation of Transcription Factor GATA4 Is Necessary for Stress-Induced Cardiac Hypertrophy in Vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 12331–12336.

(3) Arnold, H. K.; Sears, R. C. A Tumor Suppressor Role for PP2A-B56a through Negative Regulation of c-Myc and Other Key Oncoproteins. Cancer Metastasis Rev. 2008, 27, 147–158.

(4) Wang, Y.-C.; Peterson, S. E.; Loring, J. F. Protein Post-Translational Modifications and Regulation of Phlumipotency in Human Stem Cells. Cell Res. 2014, 24, 143–160.

(5) Golonzhka, O.; Liang, X.; Messaddeq, N.; Bornert, J.-M.; Campbell, A. L.; Metzger, D.; Chambon, P.; Ganguil-Indra, G.; Leid, M.; Indra, A. K. Dual Role of COUP-TF-Interacting Protein 2 in
Epidermal Homeostasis and Permeability Barrier Formation. *J. Invest. Dermatol.* 2009, 129, 1459–1470.

(6) Golonzhka, O.; Metzger, D.; Bornert, J.-M.; Bay, B. K.; Gross, M. K.; Kioussis, C.; Leid, M. Ctip2/Bcl11b Controls Ameloblast Formation during Mammalian Odontogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 2009, 106, 4278–4283.

(7) Krzylykova, K.; Kyrylenko, S.; Biehs, B.; Klein, O.; Kioussis, C.; Leid, M. BCL11B Regulates Epithelial Proliferation and Asymmetric Development of the Mouse Mandibular Incisor. *PLoS One* 2012, 7, e37670.

(8) Arlotta, P.; Molyneaux, B. J.; Jabaudon, D.; Yoshida, Y.; Macklis, J. D. Ctip2 Controls the Differentiation of Medium Spiny Neurons and the Establishment of the Cellular Architecture of the Striatum. *J. Neurosci.* 2008, 28, 622–632.

(9) Enomoto, T.; Ohmoto, M.; Iwata, T.; Uno, A.; Saitou, M.; Yamaguchi, T.; Kioussis, K.; Matsumoto, I.; Hirota, J. Bcl11b/CTIP2 Controls the Differentiation of Vomeronasal Sensory Neurons in Mice. *J. Neurosci.* 2011, 31, 10159–10173.

(10) Abu, D. I.; Feng, D.; Bhattacharya, D.; Jenkins, N. A.; Copeland, N. G.; Liu, P.; Avram, D. BCL11B Is Required for Positive Selection and Survival of Double-Positive Thymocytes. *J. Exp. Med.* 2007, 204, 3003–3015.

(11) Li, P.; Burke, S.; Wang, J.; Chen, X.; Ortiz, M.; Lee, S.-C.; Lu, D.; Campos, L.; Goulding, D.; Ng, B. L.; et al. Reprogramming of T-Cells to Natural Killer-Like Cells upon Bcl11b Deletion. *Science* 2010, 329, 85–89.

(12) Li, L.; Leid, M.; Rothenberg, E. V. An Early T-Cell Lineage Commitment Checkpoint Dependent on the Transcription Factor Bcl11b. *Science* 2010, 329, 89–93.

(13) Leid, M.; Ishmael, J. E.; Avram, D.; Shepherd, D.; Fraulob, V.; Dollé, P.; CTIP1 and CTIP2 Are Differentially Expressed during Mouse Embryogenesis. *Gene Expression Patterns* 2004, 4, 733–739.

(14) Kastner, P.; Chan, S.; Vogel, W. K.; Zhang, L.-J.; Topark-Ngarm, A.; Golonzhka, O.; Jost, B.; De Gras, S.; Gross, M. K.; Leid, M. Bcl11b Represses a Mature T-Cell Gene Expression Program in Immature CD4+CD8+ Thymocytes. *Eur. J. Immunol.* 2010, 40, 2143–2154.

(15) Ikawa, T.; Hirose, S.; Masuda, K.; Kakugawa, K.; Satoh, R.; Shibano-Satoh, A.; Kioussis, K.; Katsura, Y.; Kawamoto, H. An Essential Developmental Checkpoint for Production of the T-Cell Lineage. *Science* 2010, 329, 93–96.

(16) Bernard, O. A.; Busson-LeConiat, M.; Ballerini, P.; Mauchaffo, M.; Della Valle, V.; Monni, R.; Nguyen Khac, F.; Mercher, T.; Penard-Poorly, T.; Diella, F.; et al. A New Recurrent and Specific Cryptic Translocation, t(5;14)(q35;q32), Is Associated with Expression of the Hox11L2 Gene in T-Acute Lymphoblastic Leukemia. *Leukemia* 2001, 15, 1495–1504.

(17) Berger, R.; Dastugue, N.; Busson, M.; Van Den Akker, J.; Pérot, C.; Ballerini, P.; Hagemeijer, A.; Michaux, L.; Charrin, C.; Pages, M. P.; et al. t(5;14)/HOX11L2-Positive T-Cell Acute Lymphoblastic Leukemia. A Collaborative Study of the Groupe Francais de Cytogénétique Hématologique (GFCH). *Leukemia* 2003, 17, 1851–1857.

(18) MacLeod, R. A. F.; Nagel, S.; Kaufmann, M.; Janssen, J. W. G.; Drexler, H. G. Activation of HOX11L2 by Juxtaposition with 3′-BCL11B in an Acute Lymphoblastic Leukemia Cell Line (HPB-ALL) with t(5;14)(q35;q32.2). *Genes, Chromosomes Cancer* 2003, 37, 84–91.

(19) Kurosuwa, N.; Fujimoto, R.; Ozawa, T.; Itoyama, T.; Sadamori, N.; Isole, M. Reduced Level of the BCL11B Protein Is Associated with Adult T-Cell Leukemia/Lymphoma. *PLoS One* 2013, 8, e55147.

(20) Abbas, S.; Sanders, M.; Zeillemaker, A.; Geertsma-Kleinekoert, W. M. C.; Koenders, J. E.; Kavelaars, F. G.; Abbas, Z. G.; Mahamoud, S.; Chu, I. W. T.; Hoogenboezem, R. Integrated Genome-Wide Genotyping and Gene Expression Profiling Reveals BCL11B as a Putative Oncogene in Acute Myeloid Leukemia with 14q32 Aberrations. *Haematologica* 2014, 99 (5), 848–857.

(21) Ganguli-Indra, G.; Wasylyk, C.; Liang, X.; Millon, R.; Leid, M.; Wasylyk, B.; Abecasis, J.; Indra, A. K.; Indra, A. CTIP2 Expression in Human Head and Neck Squamous Cell Carcinoma Is Linked to Poorly Differenitized Tumor Status. *PLoS One* 2009, 4, e5367.
(38) Rohr, O.; Lecestre, D.; Chasserot-Golaz, S.; Marban, C.; Avram, D.; Aunis, D.; Leid, M.; Schaeffer, E. Recruitment of Tat to Heterochromatin Protein HP1 via Interaction with CTIP2 Inhibits Human Immunodeficiency Virus Type 1 Replication in Microglial Cells. J. Virol. 2003, 77, 5415–5427.

(39) Senawong, T.; Peterson, V. J.; Avram, D.; Shepherd, D. M.; Frye, R. A.; Minucci, S.; Leid, M. Involvement of the Histone Deacetylase SIRT1 in Chicken Ovalbumin Upstream Promoter Transcription Factor (COUP-TF)-Interacting Protein 2-Mediated Transcriptional Repression. J. Biol. Chem. 2003, 278, 43041–43050.

(40) Marban, C.; Redel, L.; Suzanne, S.; Van Lint, C.; Lecestre, D.; Chasserot-Golaz, S.; Leid, M.; Aunis, D.; Schaeffer, E.; Rohr, O. COUP-TF Interacting Protein 2 Represses the Initial Phase of HIV-1 Gene Transcription in Human Microglial Cells. Nucleic Acids Res. 2005, 33, 2318–2331.

(41) Topark-Ngarm, A.; Golonzhka, O.; Peterson, V. J.; Barrett, B.; Martinez, B.; Crofoot, K.; Filts, T. M.; Leid, M. CTIP2 Associates with the NuRD Complex on the Promoter of p57KIP2, a Newly Identified CTIP2 Target Gene. J. Biol. Chem. 2006, 281, 32272–32283.

(42) Farrell, A. S.; Pelz, C.; Wang, X.; Daniel, C. J.; Wang, Z.; Su, Y.; Janghorban, M.; Zhang, X.; Morgan, C.; Impey, S.; et al. Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis. Mol. Cell. Biol. 2013, 33, 2930–2949.

(43) Mendoza, M. C.; Er, E. E.; Zhang, W.; Ballif, B. A.; Elliott, H. L.; Danuser, G.; Blenis, J. ERK-MAPK Drives Lamellipodia Protrusion by Activating the WAVE2 Regulatory Complex. Mol. Cell 2011, 41, 661–671.

(44) Mendoza, H.; Campbell, D. G.; Burness, K.; Haste, J.; Ronkina, N.; Shim, J.-H.; Arthur, J. S. C.; Davis, R. J.; Gaestel, M.; Johnson, G. L.; et al. Roles for TAB1 in Regulating the IL-1-Dependent Phosphorylation of the TAB3 Regulatory Subunit and Activity of the TAK1 Complex. Biochem. J. 2008, 409, 711–722.

(45) Okamura, H.; Aramburu, J.; García-Rodríguez, C.; Viola, J. P.; Raghavan, A.; Tahiliani, M.; Zhang, X.; Qin, J.; Hogan, P. G.; Rao, A. Concerted Dephosphorylation of the Transcription Factor NFAT1 Induces a Conformational Switch That Regulates Transcriptional Activity. Mol. Cell 2000, 6, 539–550.

(46) Salazar, C.; Brümmer, A.; Alberghina, L.; Höfer, T. Timing Control in Regulatory Networks by Multisite Protein Modifications. Trends Cell Biol. 2010, 20, 634–641.

(47) Kövomägi, M.; Valk, E.; Venta, R.; Iofik, A.; Lepiku, M.; Balog, E. R. M.; Rubin, S. M.; Morgan, D. O.; Loog, M. Cascades of Multisite Phosphorylation Control Sic1 Destruction at the Onset of S-Phase. Nature 2011, 480, 128–131.

(48) Niewialomski, P.; Kong, J. H.; Ahrends, R.; Ma, Y.; Humke, E. W.; Khan, S.; Teruel, M. N.; Novitch, B. G.; Rohatgi, R. Gli Protein Activity Is Controlled by Multisite Phosphorylation in Vertebrate Hedgehog Signaling. Cell Rep. 2014, 6, 168–181.